AMPICILLIN AND SULBACTAM- ampicillin sodium and sulbactam sodium injection, powder, for solution
APP Pharmaceuticals, LLC

---------

AMPICILLIN AND SULBACTAM
FOR INJECTION, USP

PHARMACY BULK PACKAGE - NOT FOR DIRECT INFUSION

Rx only
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin and Sulbactam for Injection, USP and other antibacterial drugs, Ampicillin and Sulbactam for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION:
Ampicillin and Sulbactam for Injection, USP, is a sterile, injectable antibacterial combination, consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for parenteral administration. THE INTENT OF THIS PHARMACY BULK PACKAGE IS FOR PREPARATION OF SOLUTIONS FOR IV INFUSION ONLY.

Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylate. The structural formula is:

\[
\text{C}_{16}\text{H}_{18}\text{N}_{3}\text{NaO}_{4}\text{S} \quad \text{M.W. 371.39}
\]

Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide. The structural formula is:

\[
\text{C}_{8}\text{H}_{10}\text{NNaO}_{5}\text{S} \quad \text{M.W. 255.22}
\]
Ampicillin and Sulbactam for Injection, USP parenteral combination, is available as a white to off-white dry powder for reconstitution. Ampicillin and Sulbactam for Injection, USP dry powder is freely soluble in aqueous diluents to yield pale yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL. The pH of the solutions is between 8 and 10.

Dilute solutions (up to 30 mg ampicillin and 15 mg sulbactam per mL) are essentially colorless to pale yellow. The pH of dilute solutions remains the same.

Each sterile Pharmacy Bulk Package contains 15 grams Ampicillin and Sulbactam for Injection (equivalent to 10 g ampicillin as the sodium salt plus 5 g sulbactam as the sodium salt). The sodium content per vial is 1150 mg (50 mEq) sodium. Ampicillin and Sulbactam for Injection Pharmacy Bulk Package is a vial containing a sterile preparation of ampicillin sodium and sulbactam sodium for parenteral use that contains many single doses. The Pharmacy Bulk Package is for use in a pharmacy admixture setting; it provides many single doses of ampicillin and sulbactam for injection for addition to suitable parenteral fluids in the preparation and administration for intravenous infusion (see DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE). FURTHER DILUTION IS REQUIRED BEFORE USE.

CLINICAL PHARMACOLOGY:

General

Immediately after completion of a 15-minute intravenous infusion of Ampicillin and Sulbactam for Injection, peak serum concentrations of ampicillin and sulbactam are attained. Ampicillin serum levels are similar to those produced by the administration of equivalent amounts of ampicillin alone. Peak ampicillin serum levels ranging from 109 to 150 mcg/mL are attained after administration of 2000 mg of ampicillin plus 1000 mg sulbactam and 40 to 71 mcg/mL after administration of 1000 mg ampicillin plus 500 mg sulbactam. The corresponding mean peak serum levels for sulbactam range from 48 to 88 mcg/mL and 21 to 40 mcg/mL, respectively.

The mean serum half-life of both drugs is approximately 1 hour in healthy volunteers.

Approximately 75 to 85% of both ampicillin and sulbactam are excreted unchanged in the urine during the first 8 hours after administration of Ampicillin and Sulbactam for Injection to individuals with normal renal function. Somewhat higher and more prolonged serum levels of ampicillin and sulbactam can be achieved with the concurrent administration of probenecid.

In patients with impaired renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of Ampicillin and Sulbactam for Injection in such patients should be administered less frequently in accordance with the usual practice for ampicillin (see DOSAGE AND ADMINISTRATION).

Ampicillin has been found to be approximately 28% reversibly bound to human serum protein and sulbactam approximately 38% reversibly bound.

The following average levels of ampicillin and sulbactam were measured in the tissues and fluids listed:

**TABLE A Concentration of Ampicillin and Sulbactam for Injection in Various Body Tissues and Fluids**

<table>
<thead>
<tr>
<th>Fluid or Tissue</th>
<th>Dose (grams)</th>
<th>Ampicillin/Sulbactam</th>
<th>Concentration (mcg/mL or mcg/g) Ampicillin/Sulbactam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peritoneal Fluid</td>
<td>0.5/0.5 IV</td>
<td></td>
<td>7/14</td>
</tr>
<tr>
<td>Blister Fluid (Cantharides)</td>
<td>0.5/0.5 IV</td>
<td></td>
<td>8/20</td>
</tr>
<tr>
<td>Tissue Fluid</td>
<td>1/0.5 IV</td>
<td></td>
<td>8/4</td>
</tr>
</tbody>
</table>
Penetration of both ampicillin and sulbactam into cerebrospinal fluid in the presence of inflamed meninges has been demonstrated after IV administration of ampicillin and sulbactam.

The pharmacokinetics of ampicillin and sulbactam in pediatric patients receiving ampicillin and sulbactam are similar to those observed in adults. Immediately after a 15-minute infusion of 50 to 75 mg ampicillin and sulbactam for injection/kg body weight, peak serum and plasma concentrations of 82 to 446 mcg ampicillin/mL and 44 to 203 mcg sulbactam/mL were obtained. Mean half-life values were approximately 1 hour.

**Microbiology**

Ampicillin is similar to benzyl penicillin in its bactericidal action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of cell wall mucopeptide biosynthesis. Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. (Ampicillin is, however, degraded by beta-lactamases and therefore the spectrum of activity does not normally include organisms which produce these enzymes.)

A wide range of beta-lactamases found in microorganisms resistant to penicillins and cephalosporins have been shown in biochemical studies with cell free bacterial systems to be irreversibly inhibited by sulbactam. Although sulbactam alone possesses little useful antibacterial activity except against the Neisseriaceae, whole organism studies have shown that sulbactam restores ampicillin activity against beta-lactamase producing strains. In particular, sulbactam has good inhibitory activity against the clinically important plasmid mediated beta-lactamases most frequently responsible for transferred drug resistance. Sulbactam has no effect on the activity of ampicillin against ampicillin susceptible strains.

The presence of sulbactam in the Ampicillin and Sulbactam for Injection formulation effectively extends the antibiotic spectrum of ampicillin to include many bacteria normally resistant to it and to other beta-lactam antibiotics. Thus, ampicillin and sulbactam possesses the properties of a broad-spectrum antibiotic and a beta-lactamase inhibitor.

While *in vitro* studies have demonstrated the susceptibility of most strains of the following organisms, clinical efficacy for infections other than those included in the indications section has not been documented.

**Gram-Positive Bacteria**

*Staphylococcus aureus* (beta-lactamase and non-beta-lactamase producing), *Staphylococcus epidermidis* (beta-lactamase and non-beta-lactamase producing), *Staphylococcus saprophyticus* (beta-lactamase and non-beta-lactamase producing), *Streptococcus faecalis*† (Enterococcus), *Streptococcus pneumoniae*† (formerly *D. pneumoniae*), *Streptococcus pyogenes*†, *Streptococcus viridans*†.

**Gram-Negative Bacteria**

*Haemophilus influenzae* (beta-lactamase and non-beta-lactamase producing), *Moraxella (Branhamella) catarrhalis* (beta-lactamase and non-beta-lactamase producing), *Escherichia coli* (beta-lactamase and non-beta-lactamase producing), *Klebsiella* species (all known strains are beta-lactamase producing), *Proteus mirabilis* (beta-lactamase and non-beta-lactamase producing), *Proteus vulgaris*, *Providencia rettgeri*, *Providencia stuartii*, *Morganella morganii*, and *Neisseria gonorrhoeae* (beta-lactamase and non-beta-lactamase producing).

**Anaerobes**

*Clostridium* species†, *Peptococcus* species†, *Peptostreptococcus* species, *Bacteroides* species, including *B. fragilis*.

†These are not beta-lactamase producing strains and, therefore, are susceptible to ampicillin alone.
Susceptibility Testing

Diffusion Technique

For the Kirby-Bauer method of susceptibility testing, a 20 mcg (10 mcg ampicillin + 10 mcg sulbactam) diffusion disk should be used. The method is one outlined in the NCCLS publication M2-A4.1 With this procedure, a report from the laboratory of "Susceptible" indicates that the infecting organism is likely to respond to Ampicillin and Sulbactam for Injection therapy and a report of "Resistant" indicates that the infecting organism is not likely to respond to therapy. An "Intermediate" susceptibility report suggests that the infecting organism would be susceptible to Ampicillin and Sulbactam for Injection if a higher dosage is used or if the infection is confined to tissues or fluids (e.g., urine) in which high antibiotic levels are attained.

Dilution Technique

Broth or agar dilution methods may be used to determine the minimal inhibitory concentration (MIC) value for susceptibility of bacterial isolates to ampicillin/sulbactam. The method used is one outlined in the NCCLS publication M7-A2.2 Tubes should be inoculated to contain 10^5 to 10^6 organisms/mL or plates "spotted" with 10^4 organisms.

The recommended dilution method employs a constant ampicillin/sulbactam ratio of 2:1 in all tubes with increasing concentrations of ampicillin. MIC's are reported in terms of ampicillin concentration in the presence of sulbactam at a constant 2 parts ampicillin to 1 part sulbactam.

Recommended Ampicillin/Sulbactam, Susceptibility Ranges, 1,2,3

<table>
<thead>
<tr>
<th>Gram(-) and Staphylococcus</th>
<th>Resistant</th>
<th>Intermediate</th>
<th>Susceptible</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bauer/Kirby Zone Sizes</td>
<td>≤ 11 mm</td>
<td>12 to 13 mm</td>
<td>≥ 14 mm</td>
</tr>
<tr>
<td>MIC (mcg of ampicillin/mL)</td>
<td>≥ 32</td>
<td>16</td>
<td>≤ 8</td>
</tr>
</tbody>
</table>

| Haemophilus influenza     |             |              |             |
| Bauer/Kirby Zone Sizes    | ≤ 19        | -            | ≥ 20        |
| MIC (mcg of ampicillin/mL)| ≥ 4         | -            | ≤ 2         |

1The non-beta-lactamase producing organisms which are normally susceptible to ampicillin, such as Streptococci, will have similar zone sizes as for ampicillin disks.

2Staphylococci resistant to methicillin, oxacillin, or nafcillin must be considered resistant to Ampicillin and Sulbactam for Injection.

3The quality control cultures should have the following assigned daily ranges for ampicillin/sulbactam:

<table>
<thead>
<tr>
<th></th>
<th>Disks</th>
<th>Mode MIC (mcg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. coli (ATCC 25922)</td>
<td>20 to 24 mm</td>
<td>2/1</td>
</tr>
<tr>
<td>S. aureus (ATCC 25923)</td>
<td>29 to 37 mm</td>
<td>0.12/0.06</td>
</tr>
<tr>
<td>E. coli (ATCC 35218)</td>
<td>13 to 19 mm</td>
<td>8/4</td>
</tr>
</tbody>
</table>
INDICATIONS AND USAGE:

Ampicillin and Sulbactam for Injection, USP is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.

**Skin and Skin Structure Infections** caused by beta-lactamase producing strains of *Staphylococcus aureus*, *Escherichia coli,* *Klebsiella* spp.*, (including *K. pneumoniae*), *Proteus mirabilis,* *Bacteroides fragilis,* *Enterobacter* spp.*, and *Acinetobacter calcoaceticus*.

NOTE: For information on use in pediatric patients see PRECAUTIONS, Pediatric Use and CLINICAL STUDIES sections.

**Intra-Abdominal Infections** caused by beta-lactamase producing strains of *Escherichia coli*, *Klebsiella* spp. (including *K. pneumoniae*), *Bacteroides* spp. (including *B. fragilis*), and *Enterobacter* spp.*

**Gynecological Infections** caused by beta-lactamase producing strains of *Escherichia coli,* and *Bacteroides* spp.* (including *B. fragilis*).

*Efficacy for this organism in this organ system was studied in fewer than 10 infections.

While Ampicillin and Sulbactam for Injection is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection should not require the addition of another antibiotic.

Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam for Injection.

Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies, when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate.

To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam for Injection and other antibacterial drugs, Ampicillin and Sulbactam for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS:

The use of Ampicillin and Sulbactam for Injection is contraindicated in individuals with a history of hypersensitivity reactions to any of the penicillins.

WARNINGS:

SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY THESE REACTIONS ARE MORE APT TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR HYPER-SENSITIVITY REACTIONS TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE THERAPY WITH A PENICILLIN, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, AND OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, AMPICILLIN AND SULBACTAM FOR INJECTION SHOULD BE DISCONTINUED AND THE APPROPRIATE THERAPY INSTITUTED.
SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE, OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.

_Clostridium difficile_ associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Ampicillin and Sulbactam for Injection, USP, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of _C. difficile_.

_C. difficile_ produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of _C. difficile_ cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against _C. difficile_ may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of _C. difficile_, and surgical evaluation should be instituted as clinically indicated.

**PRECAUTIONS:**

**General**

A high percentage of patients with mononucleosis who receive ampicillin develop a skin rash. Thus, ampicillin class antibiotics should not be administered to patients with mononucleosis. In patients treated with ampicillin and sulbactam the possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving _Pseudomonas_ or _Candida_), the drug should be discontinued and/or appropriate therapy instituted.

Prescribing ampicillin and sulbactam in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

**Information for Patients**

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Patients should be counseled that antibacterial drugs including ampicillin and sulbactam should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When ampicillin and sulbactam is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ampicillin and sulbactam or other antibacterial drugs in the future.

**Drug Interactions**

Probenecid decreases the renal tubular secretion of ampicillin and sulbactam. Concurrent use of probenecid with ampicillin and sulbactam may result in increased and prolonged blood levels of ampicillin and sulbactam. The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with ampicillin and sulbactam and allopurinol administered concurrently. Ampicillin and sulbactam and aminoglycosides should not be reconstituted together due to the _in vitro_ inactivation of aminoglycosides by the ampicillin component of
ampicillin and sulbactam.

**Drug/Laboratory Test Interactions**

Administration of ampicillin and sulbactam will result in high urine concentration of ampicillin. High urine concentrations of ampicillin may result in false positive reactions when testing for the presence of glucose in urine using Clinitest™, Benedict's Solution or Fehling's Solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix™) be used. Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone and estradiol has been noted. This effect may also occur with ampicillin and sulbactam.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential.

**Pregnancy**

**Pregnancy Category B**

Reproduction studies have been performed in mice, rats, and rabbits at doses up to ten (10) times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Ampicillin and Sulbactam for Injection. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed (see Drug/Laboratory Test Interactions).

**Labor and Delivery**

Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions. However, it is not known whether the use of Ampicillin and Sulbactam for Injection in humans during laborer delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.

**Nursing Mothers**

Low concentrations of ampicillin and sulbactam are excreted in the milk; therefore, caution should be exercised when Ampicillin and Sulbactam for Injection is administered to a nursing woman.

**Pediatric Use**

The safety and effectiveness of Ampicillin and Sulbactam for Injection have been established for pediatric patients one year of age and older for skin and skin structure infections as approved in adults. Use of Ampicillin and Sulbactam for Injection in pediatric patients is supported by evidence from adequate and well-controlled studies in adults with additional data from pediatric pharmacokinetic studies, a controlled clinical trial conducted in pediatric patients and post-marketing adverse events surveillance (see CLINICAL PHARMACOLOGY, INDICATIONS AND USAGE, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, and CLINICAL STUDIES).

The safety and effectiveness of Ampicillin and Sulbactam for Injection have not been established for pediatric patients for intra-abdominal infections.

**ADVERSE REACTIONS:**

**Adult Patients**

Ampicillin and Sulbactam for Injection is generally well tolerated. The following adverse reactions have been reported.

**Local Adverse Reactions**

Pain at IV injection site - 3%
Systemic Adverse Reactions

The most frequently reported adverse reactions were diarrhea in 3% of the patients and rash in less than 2% of the patients.

Additional systemic reactions reported in less than 1% of the patients were: itching, nausea, vomiting, candidiasis, fatigue, malaise, headache, chest pain, flatulence, abdominal distension, glossitis, urine retention, dysuria, edema, facial swelling, erythema, chills, tightness in throat, substernal pain, epistaxis and mucosal bleeding.

Pediatric Patients

Available safety data for pediatric patients treated with Ampicillin and Sulbactam for Injection demonstrate a similar adverse events profile to those observed in adult patients. Additionally, atypical lymphocytosis has been observed in one pediatric patient receiving Ampicillin and Sulbactam for Injection.

Adverse Laboratory Changes

Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were:

**Hepatic:** Increased AST (SGOT), ALT (SGPT), alkaline phosphatase, and LDH.

**Hematologic:** Decreased hemoglobin, hematocrit, RBC, WBC, neutrophils, lymphocytes, platelets and increased lymphocytes, monocytes, basophils, eosinophils, and platelets.

**Blood Chemistry:** Decreased serum albumin and total proteins.

**Renal:** Increased BUN and creatinine.

**Urinalysis:** Presence of RBC's and hyaline casts in urine.

The following adverse reactions have been reported with ampicillin-class antibiotics and can also occur with Ampicillin and Sulbactam for Injection.

Gastrointestinal

Gastritis, stomatitis, black “hairy” tongue and enterocolitis. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS).

Hypersensitivity Reactions

Urticaria, erythema multiforme, and an occasional case of exfoliative dermatitis have been reported. These reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, the drug should be discontinued, unless the opinion of the physician dictates otherwise. Serious and occasional fatal hypersensitivity (anaphylactic) reactions can occur with a penicillin (see WARNINGS).

Hematologic

In addition to the adverse laboratory changes listed above for Ampicillin and Sulbactam for Injection, agranulocytosis has been reported during therapy with penicillins. All of these reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Some individuals have developed positive direct Coombs Tests during treatment with Ampicillin and Sulbactam for Injection, as with other beta-lactam antibiotics.

OVERDOSAGE:

Neurological adverse reactions, including convulsions, may occur with the attainment of high CSF levels of beta-lactams. Ampicillin may be removed from circulation by hemodialysis. The molecular weight, degree of protein binding and pharmacokinetics profile of sulbactam suggest that this compound
may also be removed by hemodialysis.

CLINICAL STUDIES:

Skin and Skin Structure Infections in Pediatric Patients

Data from a controlled clinical trial conducted in pediatric patients provided evidence supporting the safety and efficacy of Ampicillin and Sulbactam for Injection for the treatment of skin and skin structure infections. Of 99 pediatric patients evaluable for clinical efficacy, 60 patients received a regimen containing intravenous Ampicillin and Sulbactam for Injection, and 39 patients received a regimen containing intravenous cefuroxime. This trial demonstrated similar outcomes (assessed at an appropriate interval after discontinuation of all antimicrobial therapy) for Ampicillin and Sulbactam for Injection- and cefuroxime-treated patients:

<table>
<thead>
<tr>
<th>Therapeutic Regimen</th>
<th>Clinical Success</th>
<th>Clinical Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin and Sulbactam</td>
<td>51/60 (85%)</td>
<td>9/60 (15%)</td>
</tr>
<tr>
<td>for Injection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>34/39 (87%)</td>
<td>5/39 (13%)</td>
</tr>
</tbody>
</table>

Most patients received a course of oral antimicrobials following initial treatment with intravenous administration of parenteral antimicrobials. The study protocol required that the following three criteria be met prior to transition from intravenous to oral antimicrobial therapy: 1) receipt of a minimum of 72 hours of intravenous therapy; 2) no documented fever for prior 24 hours; and 3) improvement or resolution of the signs and symptoms of infection.

The choice of oral antimicrobial agent used in this trial was determined by susceptibility testing of the original pathogen, if isolated, to oral agents available. The course of oral antimicrobial therapy should not routinely exceed 14 days.

DOSAGE AND ADMINISTRATION:

Ampicillin and Sulbactam for Injection, USP may be used for parenteral administration (following dilution). THE INTENT OF THIS PHARMACY BULK PACKAGE IS FOR PREPARATION OF SOLUTIONS FOR IV INFUSION ONLY.

For IV administration, the dose can be given by slow intravenous injection over at least 10 to 15 minutes or can also be delivered, in greater dilutions with 50 to 100 mL of a compatible diluent as an intravenous infusion over 15 to 30 minutes.

The recommended adult dosage of ampicillin and sulbactam is 1.5 g (1 g ampicillin as the sodium salt plus 0.5 g sulbactam as the sodium salt) to 3 g (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt) every six hours. This 1.5 to 3 g range represents the total of ampicillin content plus the sulbactam content of Ampicillin and Sulbactam for Injection, USP and corresponds to a range of 1 g ampicillin/0.5 g sulbactam to 2 g ampicillin/1 g sulbactam. The total dose of sulbactam should not exceed 4 grams per day.

Pediatric Patients 1 Year of Age or Older

The recommended daily dose of Ampicillin and Sulbactam for Injection, USP in pediatric patients is 300 mg per kg of body weight administered via intravenous infusion in equally divided doses every 6 hours. This 300 mg/kg/day dosage represents the total ampicillin content plus the sulbactam content of ampicillin and sulbactam for injection, and corresponds to 200 mg ampicillin/100 mg sulbactam per kg per day. Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations, and the total dose of sulbactam should not exceed 4 grams per day. The course of intravenous therapy should not routinely exceed 14 days. In clinical trials, most children received a course of oral antimicrobials following initial treatment with intravenous Ampicillin and Sulbactam for Injection, USP (see CLINICAL STUDIES).
Impaired Renal Function

In patients with impairment of renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of Ampicillin and Sulbactam for Injection in such patients should be administered less frequently in accordance with the usual practice for ampicillin and according to the following recommendations:

### Ampicillin and Sulbactam for Injection, USP Dosage Guide For Patients With Renal Impairment

<table>
<thead>
<tr>
<th>Creatinine Clearance (mL/min/1.73m²)</th>
<th>Ampicillin/Sulbactam Half-Life (Hours)</th>
<th>Recommended Ampicillin and Sulbactam for Injection, USP Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 30</td>
<td>1</td>
<td>1.5 to 3g q6h-q8h</td>
</tr>
<tr>
<td>15-29</td>
<td>5</td>
<td>1.5 to 3g q12h</td>
</tr>
<tr>
<td>5-14</td>
<td>9</td>
<td>1.5 to 3g q24h</td>
</tr>
</tbody>
</table>

When only serum creatinine is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function.

Males: Weight (kg) x (140 - age) / 72 x serum creatinine
Females: 0.85 x above value

**COMPATIBILITY, RECONSTITUTION AND STABILITY:**

When concomitant therapy with aminoglycosides is indicated, Ampicillin and Sulbactam for Injection, USP and aminoglycosides should be reconstituted and administered separately, due to the *in vitro* inactivation of aminoglycosides by any of the aminopenicillins.

**DIRECTIONS FOR USE:**

**General Dissolution Procedures**

Ampicillin and Sulbactam for Injection, USP sterile powder for intravenous use may be reconstituted with any of the compatible diluents described in this insert. Solutions should be allowed to stand after dissolution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization.

**Preparation for Intravenous Use**

After reconstitution of the Pharmacy Bulk Package, an appropriate volume should then be immediately diluted with a suitable parenteral diluent to yield solutions containing a concentration of 3 and 45 mg (2 to 30 mg ampicillin/1 to 15 mg sulbactam/mL).

**DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE:**

The 15 gram may be reconstituted with either 92 mL Sterile Water for Injection or 0.9% Sodium Chloride Injection. The diluent should be added in two separate aliquots in a suitable work area, such as a laminar flow hood. Add 50 mL of solution, shake to dissolve. Then add an additional 42 mL and shake. The solution should be allowed to stand after dissolution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization. The resultant solution should have a final concentration of approximately 100 mg/mL ampicillin and 50 mg/mL sulbactam. The closure may be penetrated only one time after reconstitution, if needed, using a suitable sterile transfer device or
dispensing set which allows measured dispensing of the contents.

After reconstitution, use within two hours if stored at room temperature, or within four hours if stored under refrigeration.

**Reconstituted Bulk Solution Should Not Be Used for Direct Infusion**

If the reconstituted bulk solution is stored for less than one hour at room temperature (20°C/68°F) prior to further dilution, the use periods indicated in Table A apply for the diluted solutions.

If the bulk solution is stored for one to two hours at room temperature (20°C/68°F) and then diluted with Sterile Water for Injection or 0.9% Sodium Chloride Injection to the following concentrations, the use periods indicated in Table B apply.

Any unused portions of solution that remain after the indicated time periods should be discarded.

### Table A

<table>
<thead>
<tr>
<th>Diluent</th>
<th>Maximum Concentration (mg/mL) Ampicillin and Sulbactam for Injection, USP</th>
<th>Use Periods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sterile Water for Injection, USP</td>
<td>45 (30/15)</td>
<td>8 hrs @ 21°C</td>
</tr>
<tr>
<td></td>
<td>45 (30/15)</td>
<td>48 hrs @ 4°C</td>
</tr>
<tr>
<td></td>
<td>30 (20/10)</td>
<td>72 hrs @ 4°C</td>
</tr>
<tr>
<td>0.9% Sodium Chloride Injection, USP</td>
<td>45 (30/15)</td>
<td>8 hrs @ 21°C</td>
</tr>
<tr>
<td></td>
<td>45 (30/15)</td>
<td>48 hrs @ 4°C</td>
</tr>
<tr>
<td></td>
<td>30 (20/10)</td>
<td>72 hrs @ 4°C</td>
</tr>
<tr>
<td>5% Dextrose Injection</td>
<td>30 (20/10)</td>
<td>2 hrs @ 21°C</td>
</tr>
<tr>
<td></td>
<td>30 (20/10)</td>
<td>4 hrs @ 4°C</td>
</tr>
<tr>
<td></td>
<td>3 (2/1)</td>
<td>2 hrs @ 21°C</td>
</tr>
<tr>
<td>Lactated Ringer's Injection</td>
<td>45 (30/15)</td>
<td>8 hrs @ 21°C</td>
</tr>
<tr>
<td></td>
<td>45 (30/15)</td>
<td>24 hrs @ 4°C</td>
</tr>
<tr>
<td>M/6 Sodium Lactate Injection</td>
<td>45 (30/15)</td>
<td>8 hrs @ 21°C</td>
</tr>
<tr>
<td></td>
<td>45 (30/15)</td>
<td>12 hrs @ 4°C</td>
</tr>
<tr>
<td>5% Dextrose in 0.45% Saline</td>
<td>3 (2/1)</td>
<td>4 hrs @ 21°C</td>
</tr>
<tr>
<td></td>
<td>15 (10/5)</td>
<td>4 hrs @ 4°C</td>
</tr>
<tr>
<td>10% Invert Sugar</td>
<td>3 (2/1)</td>
<td>4 hrs @ 21°C</td>
</tr>
<tr>
<td></td>
<td>30 (20/10)</td>
<td>3 hrs @ 4°C</td>
</tr>
</tbody>
</table>

### Table B

<table>
<thead>
<tr>
<th>IV Solution</th>
<th>Maximum Concentration (mg/mL) Ampicillin and Sulbactam for Injection, USP</th>
<th>Use Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sterile Water for Injection, USP</td>
<td>45 (30/15)</td>
<td>4 hrs @ 21°C</td>
</tr>
<tr>
<td></td>
<td>45 (30/15)</td>
<td>24 hrs @ 4°C</td>
</tr>
<tr>
<td>0.9% Sodium Chloride Injection, USP</td>
<td>45 (30/15)</td>
<td>4 hrs @ 21°C</td>
</tr>
<tr>
<td></td>
<td>45 (30/15)</td>
<td>24 hrs @ 4°C</td>
</tr>
</tbody>
</table>

**Animal Pharmacology**

While reversible glycogenosis was observed in laboratory animals, this phenomenon was dose- and
time-dependent and is not expected to develop at the therapeutic doses and corresponding plasma levels attained during the relatively short periods of combined ampicillin/sulbactam therapy in man.

**HOW SUPPLIED:**

Ampicillin and Sulbactam for Injection, USP, a sterile off-white dry powder, is available in the Pharmacy Bulk Package containing ampicillin sodium and sulbactam sodium equivalent to 10 g ampicillin and 5 g sulbactam.

<table>
<thead>
<tr>
<th>Product No.</th>
<th>NDC No.</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>307062</td>
<td>63323-370-62</td>
<td>15 grams</td>
</tr>
</tbody>
</table>

Packaged individually.

Ampicillin and Sulbactam for Injection, USP powder should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature], prior to reconstitution.

Ampicillin and Sulbactam for Injection, USP are also available as:

<table>
<thead>
<tr>
<th>Product No.</th>
<th>NDC No.</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>306820</td>
<td>63323-368-20</td>
<td>1.5 grams</td>
</tr>
<tr>
<td>306920</td>
<td>63323-369-20</td>
<td>3 grams</td>
</tr>
</tbody>
</table>

Packaged in tens.

**REFERENCES:**


Manufactured for:

[APP Pharmaceuticals, LLC](https://www.apppharmaceuticals.com)

Made in Italy

Revised: November 2007

451033A

800843/01

**PRINCIPAL DISPLAY PANEL - Pharmacy Bulk Package**

NDC 63323-370-62

307062

AMPICILLIN AND SULBACTAM FOR INJECTION, USP
15 gram*

PHARMACY BULK PACKAGE-
NOT FOR DIRECT INFUSION

For Intravenous Use

THIS PHARMACY BULK PACKAGE IS NOT TO BE DISPENSED AS A UNIT.

Rx only

One Vial

AMPICILLIN AND SULBACTAM
FOR INJECTION, USP
15 gram*

For Intravenous Use

THIS PHARMACY BULK PACKAGE IS NOT TO BE DISPENSED AS A UNIT.

Rx only

One Vial

Manufactured for:
APP Pharmaceuticals, LLC
Schaumburg, IL 60173
Made in Italy
AMPICILLIN AND SULBACTAM
ampicillin sodium and sulbactam sodium injection, powder, for solution

Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC:63323-370</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>INTRAVENOUS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMPICILLIN SODIUM (UNII: JFN36L5S8K) (AMPICILLIN - UNII:7C782967RD)</td>
<td>AMPICILLIN</td>
<td>10 g</td>
</tr>
<tr>
<td>SULBACTAM SODIUM (UNII: DKQ4T82YE6) (SULBACTAM - UNII:S4TF6I2330)</td>
<td>SULBACTAM</td>
<td>5 g</td>
</tr>
</tbody>
</table>

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:63323-370-62</td>
<td>10 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>1 in 1 VIAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA065314</td>
<td>11/27/2006</td>
<td></td>
</tr>
</tbody>
</table>

Labeler - APP Pharmaceuticals, LLC (608775388)

Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Istituto Biochimico Italiano G. Lorenzini S.p.A.</td>
<td></td>
<td>432432581</td>
<td>manufacture(63323-370)</td>
</tr>
</tbody>
</table>

Revised: 11/2007